Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro study of fibrinogen isoforms in simulated sepsis- and trauma-induced coagulopathy
NL-OMON58114Completed
- Sponsor
- Erasmus MC
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Fibrinogen human and fibrinogen gamma prime in disseminated intravascular coagulation (DIC), trauma-induced coagulopathy (TIC) and sepsis-associated coagulopathy (SAC), sponsored by Erasmus MC. Primary endpoints: Clot formation, Inflammation parameters and 1 more. Started Jan 2026; status: completed.
02
Drugs
Fibrinogen humanfibrinogen gamma prime
03
Conditions
disseminated intravascular coagulation (DIC)trauma-induced coagulopathy (TIC)sepsis-associated coagulopathy (SAC)
Beyond the preview
Go deeper on NL-OMON58114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58114.